Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The FORECAST Study is an observational cohort study looking at two cohorts of patients presenting with COVID-19: a general public cohort, aiming to investigate if new loss or reduced sense of smell and/or taste are early signs of COVID-19 and a hospital cohort, which will investigate if taste/smell changes can predict the clinical course of a COVID-19 infection.
Description: percentage of people who report loss/reduced sense of smell or taste
Measure: Percentage of people reporting changes in smell/taste Time: 4 weeksDescription: to compare the case mortality rate in COVID-19 patients who experienced smell/taste changes compared to mortality in those who did not experience smell/taste changes.
Measure: mortality rate Time: through study completion, an average of 1 yearDescription: To identify the percentage of people who report changes in taste and/or smell before developing either fever or persistent cough who are positive for SARS-CoV-2 IgM and IgG
Measure: Percentage of people with change in smell/taste before other symptoms Time: 4 weeksDescription: To examine the proportion of other COVID-19 linked symptoms in people with smell and/or taste change who are positive positive for SARS-CoV-2 IgM and IgG who never develop fever and/or cough.
Measure: proportion of other COVID-19 linked symptoms in people with smell and/or taste change Time: 4 weeksDescription: To determine the percentage of people whose smell and/or taste symptoms persist for greater than 4 weeks in people who are positive for SARS-CoV-2 IgM and IgG
Measure: Percentage of people with persistent changes in smell and/or taste Time: 12 weeksDescription: To determine the percentage of patients who report loss/decrease in sense of smell and/or taste changes before or in the absence of other symptoms of COVID-19, who are admitted to hospital with COVID-19
Measure: Percentage of hospitalisation Time: 12 weeksDescription: To investigate whether loss/reduced sense of smell and/or taste are associated with the course of illness and outcomes in COVID-19
Measure: co-morbidities association Time: through study completion, an average of 1 yearDescription: Assessing the prevalence of previous loss/decrease in sense of smell and/or taste changes in patients admitted to secondary care with COVID-19 infection.
Measure: prevalence of changes in smell/taste Time: through study completion, an average of 1 yearDescription: Correlating the presence of loss/decrease in sense of smell and/or taste changes to clinical outcomes including case fatality rate.
Measure: clinical outcomes Time: through study completion, an average of 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports